Genocea Provides Fourth Quarter 2020 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Genocea Biosciences (GNCA) Tops Q4 EPS by 3c
February 11, 2021 7:35 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21).
We are extremely pleased to make progress across multiple fronts by using ATLAS unique ability to find the most relevant targets of T cell responses, said Chip Clark, Genocea... More
